{"id":238061,"date":"2026-09-09T13:51:06","date_gmt":"2026-09-09T08:21:06","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=238061"},"modified":"2026-09-09T13:51:06","modified_gmt":"2026-09-09T08:21:06","slug":"is-brooks-laboratories-a-good-buy-after-q1-fy27-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/is-brooks-laboratories-a-good-buy-after-q1-fy27-results\/","title":{"rendered":"Is Brooks Laboratories a Good Buy After Its Q1 FY27 Results?"},"content":{"rendered":"

Brooks Laboratories share price around Rs 64. 61.0% below 52-week high of Rs 164. Q1 FY27 revenue Rs 23 crore, down 10.1% YoY. loss of Rs 1.79 crore. PE 41x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Brooks Laboratories swung to a net loss of Rs 1.79 crore in Q1 FY27, as revenue also fell 10.1% to Rs 23 crore. This is a meaningful shift from the year-ago quarter, and the Brooks Laboratories share price should be evaluated against this profitability reset rather than the topline trend alone before calling it a good buy.<\/p>\n<\/p><\/div>\n

The Brooks Laboratories share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Brooks Laboratories is a manufacturer of pharmaceutical formulations including IV fluids, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.<\/p>\n

Revenue for the quarter came in at Rs 23 crore, down 10.1% year on year, while the company reported a net loss of Rs 1.79 crore. That combination of numbers is exactly what this article breaks down, along with what it means for the Brooks Laboratories share price from here.<\/p>\n

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Brooks Laboratories share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n